ACCELERATE DIAGNOSTICS INC (AXDX)
US00430H2013 - Common Stock
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023
AXDX stock results show that Accelerate Diagnostics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Accelerate Diagnostics (NASDAQ:AXDX) just reported results for the fourth quart...
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
/PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023. "In...
Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results.
/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30...
Accelerate Diagnostics prices $15M public offering and private placement, shares fall
Accelerate Diagnostics (NASDAQ:AXDX) said Friday it priced an underwritten public offering of units and a concurrent private placement to raise up to $15...
Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement
/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of...
Accelerate Diagnostics announces launch of proposed public offering (NASDAQ:AXDX)
Accelerate Diagnostics announces a proposed public offering of 4.5 million units consisting of common stock and warrants to purchase additional shares.
Accelerate Diagnostics Announces Launch of Proposed Public Offering
/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000...
Accelerate Diagnostics expects 2023 revenue to fall Y/Y (NASDAQ:AXDX)
Accelerate Diagnostics expects a decline in revenue for 2023 due to challenges in the capital sales environment.
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results
/PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient...
Accelerate Diagnostics announces equity offering (NASDAQ:AXDX)
Accelerate Diagnostics announced a stock offering to fund their Wave program, repay convertible senior notes, and for general corporate purposes.
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a...
Accelerate Diagnostics Reports Third Quarter 2023 Results
/PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023. "During the...
Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.
/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30...
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results
/PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023....
Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results
/PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p....
Accelerate Diagnostics to implement 1-for-10 reverse share split (NASDAQ:AXDX)
Accelerate Diagnostics (AXDX) will conduct a reverse stock split at a ratio of 1-for-10, the company said Monday.The reverse stock split will become effective at 5:00 p.m